Testoderm Tts is a drug owned by Alza Corp. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 10, 2019. Details of Testoderm Tts's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6348210 | Methods for transdermal drug administration |
Nov, 2019
(5 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Testoderm Tts is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Testoderm Tts's family patents as well as insights into ongoing legal events on those patents.
Testoderm Tts's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Testoderm Tts's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 10, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Testoderm Tts Generic API suppliers:
Testosterone is the generic name for the brand Testoderm Tts. 15 different companies have already filed for the generic of Testoderm Tts, with Actavis Labs Ut Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Testoderm Tts's generic
Alternative Brands for Testoderm Tts
Testoderm Tts which is used for transdermal administration of a drug through non-scrotal skin., has several other brand drugs using the same active ingredient (Testosterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Acerus |
| |||
| Alza |
| |||
| Antares Pharma Inc |
| |||
| Auxilium Pharms Llc |
| |||
| Azurity |
| |||
| Besins Hlthcare |
| |||
| Eli Lilly And Co |
| |||
| Endo Operations |
| |||
| Marius Pharms Llc |
| |||
| Tolmar |
| |||
| Upsher Smith Labs |
| |||
| Verity |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Testosterone, Testoderm Tts's active ingredient. Check the complete list of approved generic manufacturers for Testoderm Tts
About Testoderm Tts
Testoderm Tts is a drug owned by Alza Corp. It is used for transdermal administration of a drug through non-scrotal skin. Testoderm Tts uses Testosterone as an active ingredient. Testoderm Tts was launched by Alza in 1997.
Approval Date:
Testoderm Tts was approved by FDA for market use on 18 December, 1997.
Active Ingredient:
Testoderm Tts uses Testosterone as the active ingredient. Check out other Drugs and Companies using Testosterone ingredient
Treatment:
Testoderm Tts is used for transdermal administration of a drug through non-scrotal skin.
Dosage:
Testoderm Tts is available in film, extended release form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/24HR | FILM, EXTENDED RELEASE | Discontinued | TRANSDERMAL |